PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'From the Department of Neurology (J.G., O.A., P.A., H.-P.H.), University Hospital, Medical Faculty Heinrich Heine University, Düsseldorf, Germany; Department of Neurology (J.M.), Palacky University, Olomouc, Czech Republic; Department of Neurology, Brain and Mind Centre (M.B., H.-P.H.), Department of Neurology, University of Sydney, New South Wales, Australia; and Department of Neurology (S.S.Z.), UCSF Weill Institute of Neurosciences, University of California at San Francisco.\', \'From the Department of Neurology (J.G., O.A., P.A., H.-P.H.), University Hospital, Medical Faculty Heinrich Heine University, Düsseldorf, Germany; Department of Neurology (J.M.), Palacky University, Olomouc, Czech Republic; Department of Neurology, Brain and Mind Centre (M.B., H.-P.H.), Department of Neurology, University of Sydney, New South Wales, Australia; and Department of Neurology (S.S.Z.), UCSF Weill Institute of Neurosciences, University of California at San Francisco. hans-peter.hartung@uni-duesseldorf.de.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • e91910.1212/NXI.0000000000000919
?:hasPublicationType
?:journal
  • Neurology(R) neuroimmunology & neuroinflammation
is ?:pmid of
?:pmid
?:pmid
  • 33411674
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all